Nicola Dagg > Kirkland & Ellis International LLP > London, England > Lawyer Profile

Kirkland & Ellis International LLP houses a ‘talented and experienced‘ team, which is noted for its strength in IP disputes, follow on damages cases, and M&A. Daniel Lim, ‘titan of IP litigation‘ Nicola Dagg, and Emma Flett jointly lead the practice. ‘Top-class litigator‘ Lim acts for a clients in disputes concerning medical devices and pharmaceutical products, often in relation to commercial launches and injunctions. Hailed by clients as ‘one of the outstanding patent litigators of current times‘, Dagg regularly defends patents against challenges from generics manufacturers. Litigator Jin Ooi has broad expertise in small molecule, DNA sequencing, and transgenic animal platform issues, displaying ‘laser sharp focus‘ when arbitrating trade secrets disputes in the medical devices space. Since publication, Katie Coltart has moved to Linklaters LLP.

‘Top-class’ Kirkland & Ellis International LLP maintains a strong IP offering, routinely handling high-stakes disputes, one notable example being the team’s representation of Pfizer and Regeneron in landmark judgments in the Supreme Court. The team of ‘ferocious litigators’ also has experience of handling SEP/FRAND related litigation. On the transactional side, the team is involved in M&A deals, as well as multiple asset deals and carve-out transactions. Nicola Dagg spearheads the IP litigation practice, she has a wealth of experience in managing biotech patent litigations, as well as an expertise in emerging SEP/FRAND related work. Daniel Lim is noted for his ability to handle complex multijurisdictional patent litigation, often involving blockbuster life sciences and medical devices related matters, while IP litigator Steven Baldwin is well-versed in the high-tech and life sciences sectors. ‘Strategic thinker’ Jin Ooi fields a strong IP litigation practice, with his expertise in the biotechnology space. Emma Flett leads the firm’s technology and IP transactions team with her capabilities that encompass the full gamut of IP-related work, but especially in regard to high-value M&A transactions.